Trial Profile
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women With Low Bone Mass
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Romosozumab (Primary)
- Indications Bone resorption; Male osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Amgen
- 23 Nov 2013 Results published in the Journal of Clinical Pharmacology.
- 11 Apr 2013 New source identified and integrated: ClinicalTrials.gov record.
- 29 Jun 2012 New trial record